- Home
- ARAY vs SCLX Comparison
ARAY vs SCLX Comparison
Compare ARAY & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARAY
- SCLX
- Stock Information
- Founded
- ARAY 1990
- SCLX 2011
- Country
- ARAY United States
- SCLX United States
- Employees
- ARAY N/A
- SCLX N/A
- Industry
- ARAY Medical/Dental Instruments
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- ARAY Health Care
- SCLX Health Care
- Exchange
- ARAY Nasdaq
- SCLX Nasdaq
- Market Cap
- ARAY 170.1M
- SCLX 139.3M
- IPO Year
- ARAY 2007
- SCLX N/A
- Fundamental
- Price
- ARAY $1.03
- SCLX $20.16
- Analyst Decision
- ARAY Strong Buy
- SCLX Hold
- Analyst Count
- ARAY 2
- SCLX 1
- Target Price
- ARAY $4.50
- SCLX N/A
- AVG Volume (30 Days)
- ARAY 1.2M
- SCLX 153.7K
- Earning Date
- ARAY 11-05-2025
- SCLX 11-14-2025
- Dividend Yield
- ARAY N/A
- SCLX N/A
- EPS Growth
- ARAY N/A
- SCLX N/A
- EPS
- ARAY N/A
- SCLX N/A
- Revenue
- ARAY $450,902,000.00
- SCLX $40,360,000.00
- Revenue This Year
- ARAY $5.70
- SCLX $89.26
- Revenue Next Year
- ARAY $4.05
- SCLX $203.95
- P/E Ratio
- ARAY N/A
- SCLX N/A
- Revenue Growth
- ARAY 1.51
- SCLX N/A
- 52 Week Low
- ARAY $0.91
- SCLX $3.60
- 52 Week High
- ARAY $2.95
- SCLX $34.27
- Technical
- Relative Strength Index (RSI)
- ARAY 33.99
- SCLX 55.78
- Support Level
- ARAY $0.91
- SCLX $19.43
- Resistance Level
- ARAY $1.46
- SCLX $27.00
- Average True Range (ATR)
- ARAY 0.07
- SCLX 2.45
- MACD
- ARAY 0.00
- SCLX 0.38
- Stochastic Oscillator
- ARAY 34.08
- SCLX 42.09
About ARAY Accuray Incorporated
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.